<p>The oral TDLo in humans 5.71 mg/kg.<sup class="text-reference-group"><a class="reference-popover-link" data-content="CaymanChem: Celecoxib MSDS" href="#reference-L7610">29</a></sup></p><p>It is not advisable to administer celecoxib in patients with renal impairment or advanced hepatic impairment, as this may lead to increased serum concentrations, causing toxicity.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: CELEBREX (celecoxib) oral capsules" href="#reference-L7646">31</a></sup> Symptoms of overdose may include breathing difficulties, coma, drowsiness, gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, stomach pain, and vomiting.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA drug safety, June 28 2018" href="#reference-L3293">23</a></sup> Because serious gastrointestinal tract ulceration and bleeding can occur without preceding symptoms, patients should be monitored for signs/symptoms of gastrointestinal bleeding. Symptomatic and supportive measures should be taken in a celecoxib overdose. The induction of emesis or administration of active charcoal should take place if the patient is seen within 4 hours of celecoxib ingestion. Diuresis, urinary alkalinization, hemodialysis, or hemoperfusion may not be useful in a celecoxib overdose due to its high level of protein binding.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: CELEBREX (celecoxib) oral capsules" href="#reference-L7646">31</a></sup> </p>